Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)

NCT04704713 is registered in ClinicalTrials.gov with Clinuvel Pharmaceuticals Limited as lead sponsor.

NCT NCT04704713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04704713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)
Lead sponsor
Clinuvel Pharmaceuticals Limited
Phase
Phase 3
Overall status
Completed
Start date
May 5, 2010
Completion date
Not reported
Enrollment
31 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

polymorphic light eruption